NEW YORK (TheStreet) -- Express Scripts (ESRX) was falling 3.88% to $74.13 on Friday morning after the pharmacy benefits manager reported its fourth-quarter results and issued first-quarter guidance.
Express Scripts reported net income of $506 million, or 63 cents a share, down from $511 million, or 61 cents a share, in the same period one year earlier. The company reported record adjusted earnings per share of $1.12, which aligned exactly with analysts' estimates, according to Thomson Reuters I/B/E/S.
The company also issued EPS guidance of $4.88 to $5, while analysts expect $4.93.
"With the industry's broadest set of solutions now available on one technology platform, we enter 2014 with momentum and unique capabilities to address the needs of our clients," said Chairman and CEO George Paz in the company's statement. "Our innovative solutions, ability to successfully manage healthcare reform, and unmatched size and scale position us for long-term organic growth as we better control client costs and improve patient outcomes."
TheStreet Ratings team rates EXPRESS SCRIPTS HOLDING CO as a "buy" with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate EXPRESS SCRIPTS HOLDING CO (ESRX) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins."